Association of Serum miR-186-5p with the Prognosis of Acute Coronary Syndrome Patients after Percutaneous Coronary Intervention

Abstract

Background: Kinetic signatures and physiologic states of circulating miR-186-5p in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and their association with ACS prognosis have not been investigated. Methods: 92 ACS patients and 96 healthy controls were enrolled. Serum miR-186-5p levels in ACS patients (on admission and at different time points within one week after PCI) and controls were detected by quantitative reverse-transcription PCR. MiR-186-5p levels in serum and myocardium of rats following permanent ligation of left anterior descending coronary artery (LAD) were also measured. The predominant form of serum miR-186-5p was analyzed by comparing its absolute concentration in isolated exosomes and exosome-depleted supernatant. An average of one-year follow-up for ACS patients was performed and the incidence of major adverse cardiovascular events (MACE) was calculated. Findings: Serum miR-186-5p levels were significantly increased in ACS patients on admission compared with controls, but their high levels were gradually decreased within one week after PCI and returned to near control levels within 1~2 days after PCI. Increased serum miR-186-5p levels were negatively correlated with decreased myocardial miR-186-5p levels in rats after permanent LAD ligation. Serum miR-186-5p was mainly existed as exosome-free form rather than membrane-bound exosomes. Within one-year follow-up, ACS patients with higher miR-186-5p levels on admission exhibited a higher incidence of MACE. Cox regression analyses validated the potential values of serum miR-186-5p for prognostic evaluation in ACS patients after PCI. Interpretations: Serum miR-186-5p may act as a promising biomarker for monitoring and assessing prognosis of ACS patients after PCI. Funding Statement:This work was supported by grants from National Natural Science Foundation of China (no. 81572074 and no. 81871702) to J.-J. Wang, National Natural Science Foundation of China (no. 81401742) to J. Wu, and National Natural Science Foundation of China (no. 81572073) to J. Song. Declaration of Interests: The authors have no competing interests to declare. Ethics Approval Statement: This study was approved by the Research Ethics Committee of Jinling Hospital (2015NZGKJ-018) and was performed in accordance with the Declaration of Helsinki of 1975, as revised in 2013.